Date published: 2026-2-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

ADAMTS-18 Activators

ADAMTS-18 is a member of the A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) family of enzymes, which play critical roles in extracellular matrix (ECM) remodeling, cell adhesion, and a variety of other biological processes. These enzymes are known for their proteolytic activity on various substrates, including proteoglycans and glycoproteins. The modulation of ADAMTS-18 and other ADAMTS proteins occurs through an intricate interplay of signaling pathways, including but not limited to TGF-β, Wnt, and various cytokine-mediated pathways. These pathways can affect both the expression and activity of ADAMTS-18, thereby influencing its role in ECM turnover and cellular function. Additionally, the substrate specificity of ADAMTS-18 is guided by its thrombospondin motifs and its metalloproteinase activity, which can be modulated by endogenous inhibitors or by chemical activators.

Specific small molecules targeting ADAMTS-18 are compounds that either directly enhance the enzyme's proteolytic activity or indirectly promote its expression or function. Indirect activators could function through a variety of mechanisms, such as epigenetic modulation, affecting substrate availability, or inhibiting opposing pathways. For instance, molecules inhibiting pathways that downregulate ADAMTS-18 could serve as indirect activators. Similarly, compounds that affect the stability, folding, or post-translational modification of ADAMTS-18 could potentially serve as direct activators. Understanding the intricacies of ADAMTS-18 activation involves a multi-faceted approach, taking into consideration both direct and indirect modulation, and is an evolving field within cellular and molecular biology.

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

DNA Methyltransferase Inhibitors could affect the methylation status of the ADAMTS-18 gene, potentially increasing its expression.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$62.00
$85.00
$356.00
155
(1)

NF-κB Inhibitors could potentially upregulate ADAMTS-18 by suppressing NF-κB signaling, if NF-κB acts as a suppressor.

XAV939

284028-89-3sc-296704
sc-296704A
sc-296704B
1 mg
5 mg
50 mg
$36.00
$117.00
$525.00
26
(1)

Wnt Pathway Inhibitors may influence ADAMTS-18 by affecting Wnt signaling, which is known to be involved in ECM remodeling.

Gö 6983

133053-19-7sc-203432
sc-203432A
sc-203432B
1 mg
5 mg
10 mg
$105.00
$299.00
$474.00
15
(1)

PKC Inhibitors could influence various signaling pathways that may indirectly activate ADAMTS-18.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK/STAT Inhibitors may affect the cytokine signaling that influences ADAMTS-18 expression or activity.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK Inhibitors could affect MAPK pathways that influence ADAMTS-18.

Cobalt(II) chloride

7646-79-9sc-252623
sc-252623A
5 g
100 g
$64.00
$176.00
7
(1)

HIF-1α Stabilizers could potentially influence the hypoxia-related activation or expression of ADAMTS-18.